Jump to content

Draft:Fractyl Health

From Wikipedia, the free encyclopedia
  • Comment: Article is promotional, and sourced almost entirely to announcements about its products, rather than about the company itself. Ref. 2 is probably fine, but the others are routine announcements and/or not about the company. Please tone down promotional content and emphasize secondary coverage of Fractyl (not its products) in reliable sources, ideally for a general audience (trade publications are fine but shouldn't form the backbone of the article). WeirdNAnnoyed (talk) 12:09, 4 March 2025 (UTC)

 Comment: In addition to making some edits, listing what I believe is the most significant coverage of this org (also cited in the article) in case it's helpful in reviewing:

  • Baxter, Amy (10 February 2025). "Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments". PharmaVoice. Retrieved 7 March 2025.
  • DeFeudis, Nicole (16 June 2021). "After a decade in the type 2 diabetes game, Fractyl Laboratories recharges with a fresh $100M and a new name". Endpoints News. Archived from the original on 16 June 2021. Retrieved 10 January 2025.
  • Fonseca, Camilo (18 January 2024). "Lexington-based Fractyl Health, focused on non-drug treatments for diabetes and obesity, filing for IPO". The Lexington Observer. Retrieved 9 January 2025.
  • Lawrence, Stacy (14 October 2015). "FierceMedicalDevices' 2015 Fierce 15". Fierce Biotech. Retrieved 20 May 2025.

Thank you! Mary Gaulke (talk) 15:19, 20 May 2025 (UTC)

Fractyl Health, Inc.
FormerlyFractyl Laboratories
Company typePublic
Nasdaq: GUTS
Industry
Founded2010; 15 years ago (2010)
Founders
  • Jay Caplan
  • Harith Rajagopalan
Headquarters
Burlington, Massachusetts
Key people
Number of employees
88[2] (2024)
Websitefractyl.com

Fractyl Health is a Burlington, Massachusetts-based[3] healthcare company focused on metabolic diseases like obesity and type 2 diabetes.[4] The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).

History

[edit]

Harith Rajagopalan, MD, PhD, and Jay Caplan established Fractyl Health, initially named Fractyl Laboratories,[5] in 2010.[6] The company's Revita device gained CE marking in April 2016[7] and became commercially available in the UK in January 2020.[8] In April 2021, the US Food and Drug Administration (FDA) gave Revita breakthrough device designation to treat type 2 diabetes.[9] The company changed its name to Fractyl Health in June 2021.[10]

In April 2022, the FDA approved an investigational device exemption trial for Revita.[11] It became available commercially in Germany in early 2023.[12] The FDA issued additional breakthrough device designation to Revita in July 2024 for weight maintenance in certain people with type 2 diabetes or obesity.[13][14]

Fractyl had an initial public offering on the Nasdaq in February 2024.[15] As of February 2025,[16] the company's REMAIN-1 study is evaluating Revita for patients with obesity to support weight maintenance after use of a GLP-1 drug.[17] In January 2025, Fractyl announced it would focus research for Revita on obesity and people on GLP-1s,[18] citing rising demand driven by the popularity of GLP-1s.[19] The company also laid off some employees focused on type 2 diabetes treatment.[20]

Products

[edit]

Fractyl's therapies focus on the root causes of metabolic diseases like obesity.[4]

Revita

[edit]

Revita is an outpatient endoscopic procedure that resurfaces the mucosal lining of the duodenum using ablation with water and heat.[13][21] The duodenal lining can thicken with chronic high-fat and high-sugar diets;[22] this can damage signaling mechanisms in the gastrointestinal tract[13] and lead to metabolic disease.[23][24] After resurfacing, a healthy mucosal layer can regrow over time, potentially improving blood sugar regulation[5] and insulin sensitivity.[22]

Rejuva

[edit]

Rejuva is an adeno-associated virus (AAV)-based gene therapy platform to enable the pancreas to produce GLP-1 on an ongoing basis as a treatment for obesity and type 2 diabetes.[25] The therapy targets dysfunctional beta islet cells in the pancreas.[26] Delivery is done with a needle catheter to deliver viral vectors into the pancreas.[26]

In January 2025, Rejuva completed Clinical Trial Application-enabling preclinical in vivo studies,[27] beginning its first-in-human studies in the first half of 2025.[28]

References

[edit]
  1. ^ LaHucik, Kyle (29 January 2024). "Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO". Endpoints News. Retrieved 10 January 2025.
  2. ^ Fonseca, Camilo (18 January 2024). "Lexington-based Fractyl Health, focused on non-drug treatments for diabetes and obesity, filing for IPO". The Lexington Observer. Retrieved 9 January 2025.
  3. ^ "Form 8-K: Fractyl Health, Inc". U.S. Securities and Exchange Commission. 24 June 2024. Retrieved 13 January 2025.
  4. ^ a b "Fractyl Health valued at $654.6 mln in tepid debut". Reuters. 2 February 2024. Retrieved 9 January 2025.
  5. ^ a b Hale, Conor (16 June 2021). "Fractyl nets $100M to complete development of its intestine-resurfacing device for Type 2 diabetes". Fierce Biotech. Retrieved 9 January 2025.
  6. ^ Green, Hannah (2 February 2024). "Lexington biotech raises $110M in first Mass. IPO of 2024". Boston Business Journal. Retrieved 10 January 2025.
  7. ^ "Fractyl Completes $44M Series D Financing". FinSMEs. 30 November 2017. Retrieved 10 January 2025.
  8. ^ Kent, Chloe (28 January 2020). "Revita type II diabetes treatment launches in London". Medical Device Network. Retrieved 10 January 2025.
  9. ^ Whooley, Sean (27 April 2021). "FDA grants breakthrough nod for Fractyl's type 2 diabetes treatment". Drug Delivery Business. Retrieved 9 January 2025.
  10. ^ DeFeudis, Nicole (16 June 2021). "After a decade in the type 2 diabetes game, Fractyl Laboratories recharges with a fresh $100M and a new name". Endpoints News. Archived from the original on 16 June 2021. Retrieved 10 January 2025.
  11. ^ Whooley, Sean (4 April 2022). "FDA approves IDE trial for Fractyl Health's diabetes reversal tech in type 2 diabetes patients". Drug Delivery Business. Retrieved 9 January 2025.
  12. ^ "Fractyl's Revita DMR System commercially available in Germany". Bariatric News. 8 February 2023. Retrieved 10 January 2025.
  13. ^ a b c Barrie, Robert (8 August 2024). "Fractyl Health touts positive year-long weight loss results for Revita device". Clinical Trials Arena. Retrieved 9 January 2025.
  14. ^ Gallagher, Ashley (1 August 2024). "FDA Grants Breakthrough Device Designation for System Maintaining Weight Loss After GLP-1". Pharmacy Times. Retrieved 13 January 2025.
  15. ^ "Fractyl Health raises $110 mln in US IPO". Reuters. 2 February 2024. Retrieved 9 January 2025.
  16. ^ Beard, David (9 February 2025). "WVU Medicine leads trial of procedure to maintain weight loss without GLP-1 drugs". The Dominion Post. Retrieved 7 March 2025.
  17. ^ Philpott, Jenna (2 April 2024). "Fractyl Health receives IDE approval for Revita trial". Clinical Trials Arena. Retrieved 13 January 2025.
  18. ^ Hale, Conor (31 January 2025). "Fractyl Health pivots Type 2 diabetes device therapy toward obesity and GLP-1s, lays off 17% of staff". Fierce Biotech. Retrieved 24 February 2025.
  19. ^ Baxter, Amy (10 February 2025). "Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments". PharmaVoice. Retrieved 7 March 2025.
  20. ^ Green, Hannah (31 January 2025). "Burlington biotech slims down 17% of workforce, focuses on weight maintenance treatment". Boston Business Journal. Retrieved 7 March 2025.
  21. ^ Lawrence, Stacy (14 October 2015). "FierceMedicalDevices' 2015 Fierce 15". Fierce Biotech. Retrieved 20 May 2025.
  22. ^ a b Hale, Conor (23 May 2022). "Fractyl's Type 2 diabetes device therapy spurs pancreas function". Fierce Biotech. Retrieved 10 January 2025.
  23. ^ Patchen, Tyler (1 April 2024). "Fractyl Secures FDA Approval for Weight Maintenance Study After Discontinuation of GLP-1s". BioSpace. Retrieved 13 January 2025.
  24. ^ Godkin, David (17 August 2023). "A little intestinal fortitude sees Fractyl on track to reverse the root causes of T2D". BioWorld. Retrieved 13 January 2025.
  25. ^ Grinstein, Jonathan D. (23 June 2024). "Fractyl Health's GLP-1 Gene Therapy Outperforms Semaglutide in Mice". Inside Precision Medicine. Retrieved 9 January 2025.
  26. ^ a b Floersh, Helen (24 June 2024). "Fractyl's GLP-1 gene therapy makes weight loss last in mice". Fierce Biotech. Retrieved 10 January 2025.
  27. ^ Ford, Omar (31 January 2025). "Fractyl to Lay Off 17% of Workforce". Medical Device and Diagnostic Industry. Retrieved 24 February 2025.
  28. ^ Samorodnitsky, Dan (31 January 2025). "Fractyl Goes All In on GLP-1 Off-Ramp Drug, Lays of 17% of Workforce". BioSpace. Retrieved 24 February 2025.
This page will be placed in the following categories if it is moved to the article namespace.
Categories:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Fractyl_Health&oldid=1299000018"